A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2026

Conditions

Single Ascending DoseHealthy Subjects

Interventions

BIOLOGICAL

GR2301 injection

IL15 monoclonal antibody

Trial Locations (1)

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY